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Selective mutism is a pediatric psychiatric disorder that occurs when a child
consistently fails to speak in specific situations in which speaking is expected,
such as at school and social gatherings, but speaks appropriately in other
settings.  Selective mutism often is diagnosed when a child starts school and
does not talk to teachers or peers, but talks to family members at home; the
condition is frequently accompanied by anxiety and shyness.  Although the
underlying etiology of the condition remains unclear, psychotherapy is the
preferred initial treatment, with the support of parents and teachers.  If the
child does not respond to psychotherapy, addition of pharmacologic treatment
should be considered, depending on the severity of symptoms and presence of
other illnesses.  Although data are limited to case reports and trials with small
patient populations and short follow-up periods, some patients with selective
mutism respond to therapy with selective serotonin reuptake inhibitors
(SSRIs).  Fluoxetine is the most studied SSRI as treatment for the condition,
although further investigation is required to determine the optimal dosage
and duration of therapy.
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Conclusion
Selective mutism is a psychiatric disorder that
occurs in children.  The condition is characterized
by consistent failure to speak in specific
situations in which speaking is expected, such as
at school and social gatherings, despite speaking
in other settings.1 Children with selective
mutism can speak and comprehend the spoken
language, but they withhold speech under certain
conditions.  Although relatively uncommon and
generally self-limited, selective mutism can affect
a child’s socialization and academic development.
Therapy consists of psychotherapy with or
without pharmacologic intervention.
The terminology used to describe selective
mutism has changed over the years as under-
standing of the disorder has evolved.2–4 Initially
observed in 1877 by Kaussmaul, the disorder was
termed aphasia voluntaria, which emphasized
that children were making a voluntary decision
to withhold speech.  Elective mutism was the
term used until publication of the Diagnostic and
Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) in 1994, at which time the
current term, selective mutism, was adopted.5
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This term implies a true inability to speak in
select situations rather than an elective decision
to withhold speech.
Etiology and Predisposing Factors
It is not known whether selective mutism
stems from a social phobia, or another anxiety or
psychiatric disorder, such as obsessive-compulsive
disorder or development disorder/delay.2–4, 6–9 The
pathogenesis of the condition is likely multi-
factorial.  Selective mutism was once thought to
be due to physical or emotional trauma to the
child, thus a psychodynamic approach to therapy
was advocated.  However, in one case series,
trauma, loss of a significant person, or other
personal or family crisis accounted for the onset
of selective mutism in only one third of 100
children with the diagnosis.10
Selective mutism has been characterized as a
motivational disorder in that some children
withhold speech because of severe situational
anxiety.6 Some researchers believe that mutism is
a learned behavior reinforced by the child’s
environment, and that some children may
withhold speech for manipulative purposes.11
Selective mutism has also been described as a
manifestation of family dysfunction, with the
child’s silence the result of oppositional behavior.3, 6
Instead, it appears that biologically mediated
shy temperament and anxiety may be key
components in the etiology of selective mutism
for most affected children.4, 8, 10, 12 Frequently, an
affected child has a family history of selective
mutism, shyness, or anxiety disorder in a close
relative—particularly a parent—indicating a
potential genetic link.3, 7, 13, 14 In one report,
taciturnity (being habitually reserved and non-
communicative) was 2.5 times more frequent in
first- than in third-degree relatives of children
with selective mutism.13 In another study, 70%
and 37% of affected children had first-degree
relatives with a history of selective mutism and
either social phobia or avoidant disorder,
respectively.7 Specific chromosomal abnormalities,
namely deletion of the short arm of chromosome
18, have been documented in two patients with
selective mutism accompanied by similar patterns
of speech delay and facial dysmorphisms.15, 16
In addition to family history, factors that may
predispose children to the development of
selective mutism include immigration, early
developmental risk factors (e.g., complications
during pregnancy and delivery, premorbid speech
or language disorders), and behavioral abnor-
malities.10 Selective mutism frequently overlaps
with other social anxiety disorders, and most
affected children meet the diagnostic criteria for
social phobia or avoidant disorder.7, 12, 17 In one
study, 38 of 100 children with selective mutism
had a speech and language disorder, such as
difficulty with articulation or expressive
language, before developing selective mutism.10
Poor understanding and criticism of the affected
child’s speech, resulting in embarrassment and
lowered self-esteem, may lead to withdrawal and
the development of selective mutism.  In
addition, 72% of children with selective mutism
had a history of behavioral abnormalities, such as
relationship problems, separation anxiety, and
eating or sleep disorders during infancy and
preschool age.10
Epidemiology
Selective mutism is rare and accounts for less
than 1% of all patients seen in mental health
settings.1 The reported incidence of selective
mutism ranges from 0.18–2.0%.18–20 Differences
in diagnostic criteria probably influence this
variability.  Selective mutism is 1.5–2.5 times
more common in girls than boys.7, 10, 12–14, 19 No
racial predilection has been documented, and its
occurrence does not seem to be affected by
socioeconomic status,14 although some reports
have documented a higher prevalence in middle-
class children.9, 13
Clinical Presentation and Diagnosis
According to the DSM-IV-TR (Text Revision), a
diagnosis of selective mutism requires failure to
speak in specific situations in which speaking is
expected, despite speaking at other times.1 In
addition, the lack of speaking must interfere with
achievement in school or social communication,
persist for at least 1 month, and not be associated
with an underlying developmental or psychiatric
disorder. Selective mutism must be differentiated
from mutism with an organic cause.  With
organic mutism, inability to speak is associated
with hearing loss; brain tumor; or damage to the
frontal lobe, brain stem, thalamus, or cerebellum
as a result of insults such as trauma, infection, or
surgery.21
Psychiatric disorders, including pervasive
developmental disorder, schizophrenia, and
mental retardation, may also manifest with lack
of speech.3 These disorders must be ruled out
before selective mutism can be diagnosed.1, 3, 21
In addition, children whose primary language is
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not English, and whose failure to speak is due to
lack of knowledge or comfort with spoken English,
are not considered to have selective mutism.
The onset of selective mutism is often
insidious, occurring in the preschool years in
over 80% of patients.14 The condition is usually
not diagnosed until the child has started school
at age 5–6 years, although it can develop in older
children as well.  If the child speaks at home, the
parents may not be aware of the disorder.  In one
analysis, shyness was documented in 85% of
children with selective mutism.10 Whereas shy
children eventually warm up to others and start
communicating within the first month of school,
those with selective mutism do not.  Teachers
often have the most accurate information about
the child’s symptoms since school is the most
common site for the failure to speak.
The extent of inhibition due to selective
mutism can vary; severity of the condition is
proportional to the severity of the child’s social
anxiety.3, 20, 22 Some children avoid eye contact
and withdraw completely in a social situation;
others continue to make facial expressions and
communicate nonverbally.  Gestures, nodding or
shaking the head, or monosyllabic sounds may
be used to communicate.1 Concomitant
symptoms may include enuresis and encopresis
(fecal soiling), obsessive-compulsive features,
and sleeping and eating disorders.9, 10, 14
Selective mutism is generally self-limiting and
may resolve spontaneously within a few weeks or
months.  In some patients, however, selective
mutism and its accompanying conditions may
persist for 20–30 years.23 In a follow-up study of
45 patients with selective mutism, complete
remission or remarkable improvement occurred
in 28 (62%) after 3–15 years.23 Compared with
controls, patients with a history of selective
mutism were less independent, less motivated
with respect to education, and less self-confident.
Of 25 patients who could be interviewed, 22
(88%) described their selective mutism as a
serious problem associated with intense suffering.
In another study, after a mean follow-up of 13
years, the rate of total resolution or marked
improvement in patients with selective mutism
was 82%.24 However, a higher frequency of
psychiatric disorders—especially phobic
disorder—was documented in 33 patients
compared with an age- and sex-matched control
group (p<0.005).
A comprehensive evaluation, including the
child’s medical and developmental history, family
history, and speech patterns, is essential to assess
possible causes of the lack of speech and to
identify comorbid conditions.2, 3 Essentially,
selective mutism is a disease of exclusion that is
diagnosed after other causes of the lack of speech
have been ruled out.  Correct diagnosis is crucial
because inappropriate treatment may worsen the
condition by exacerbating anxiety.  A physical
examination, including a formal speech and
language assessment, should be conducted to
identify neurologic, psychiatric, audiologic, and
speech disorders.  Of note, although with
selective mutism the speech disturbance is
restricted to a specific social situation, this is not
the case with phonologic (related to speech
sound) or expressive language disorders.
Standardized psychologic testing may be
needed to assess academic status and evaluate for
learning disabilities.  Testing should include
components of receptive language, expressive
language, and phonology.  Social interactions
may be assessed through play or art therapy or
through interviews with the child’s teacher.  An
observational interview can provide useful
information regarding the child’s temperament,
quality of interaction, and ability to communicate
verbally and nonverbally. In addition, a parental
interview may yield information about the child’s
developmental history and about speech patterns
both inside and outside the home.
Treatment
The clinical significance of selective mutism
can be argued, since the condition is generally
self-limiting, resolving after several months in
many cases.  Medical attention may not be
sought.  However, selective mutism may persist
for years, interfering with educational achieve-
ment, self-esteem, and socialization, with
potential long-term consequences.20, 23, 25
Practitioners should consider the context,
severity, and duration of selective mutism when
determining appropriate therapy.  Several
approaches have been used, including both
psychotherapy and pharmacotherapy.
Participation of family members in designing
and implementing the treatment plan is critical.
Punishment or coercion to force speech should
be avoided; instead, a supportive environment
should be provided in which speech can develop
gradually.  A school-based, individualized
treatment plan involving the parents, teacher,
health care provider, and possibly a speech
therapist may reduce the child’s anxiety and
encourage communication.3, 8, 26 Treatment
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should focus on improving basic communication
skills, which will allow the child to participate
more readily in settings where speech is expected
and reduce potential long-term detrimental
effects of selective mutism.21
Psychotherapy
At one time, psychodynamic therapy focusing
on identification and resolution of underlying
psychologic conflicts was the preferred treatment
of selective mutism.3, 8, 22, 27 Because the child
might not speak during sessions, therapists can
use special art or play techniques to initiate
communication.  However, psychodynamic
therapy can be time consuming, requiring long-
term weekly sessions.
Over the last 2 decades, behavioral interven-
tions or a combination of cognitive and behavioral
techniques have become more commonly used as
initial treatment for young children with selective
mutism.  Behavioral therapy is directed at
removing all reinforcement of the mutism by
gradually exposing the child to social situations
and providing opportunities to practice
communication.  Specific strategies include
positive reinforcement of verbal and nonverbal
behaviors (contingency management and
shaping) in conjunction with stimulus-fading
interventions.  In the latter, rewards are given for
gradual increases in the number of people spoken
to or situations spoken in.  Relaxation techniques
are taught that enable the child to manage
increasing levels of speech-related anxiety with
exposure to new speaking situations (systemic
desensitization).
With cognitive therapy, clinical psychologists
and other health care professionals seek to
increase self-confidence and decrease anxiety by
modifying self-expectations in social interactions.
The child is helped to identify and change
thoughts that reinforce mutism.  In addition,
techniques are developed to help the child
recognize and cope with physiologic and
psychologic indicators of emotional stress.
Family therapy as a primary intervention for
selective mutism has not been systematically
studied, although this approach can be useful if
family issues are identified that may affect the
child’s condition.3, 8, 27 Speech therapy may
benefit children with fluency or articulation
problems; however, this approach appears to be
less effective than cognitive-behavioral therapy or
pharmacotherapy alone or in combination.22, 27
Pharmacotherapy
Although psychotherapy plays an important
role in the initial treatment of selective mutism,
some patients may not respond.  Addition of
pharmacotherapy should then be considered,
particularly for children whose condition is
chronic or severe.3, 28 Currently, no drugs are
approved by the United States Food and Drug
Administration (FDA) for treatment of selective
mutism.  In addition, reflecting the low
prevalence of the condition, the literature
consists mainly of case reports and clinical trials
with relatively small patient populations.  Yet
despite scant published data regarding
pharmacologic management, 71 (36%) of 199
child and adolescent psychiatrists responding to
a survey have prescribed psychotropic agents—
most commonly antidepressants—for patients
with selective mutism.29 Drugs prescribed
include phenelzine30, 31 and selective serotonin
reuptake inhibitors (SSRIs).32–43
Phenelzine
Phenelzine, an irreversible, nonselective
monoamine oxidase inhibitor, was effective in
four children with selective mutism described in
two reports.30, 31 The children, aged 5–7 years,
received phenelzine 30–60 mg/day. In the first
report, phenelzine 7.5 mg 3 times/day (1
mg/kg/day) was started in a 7-year-old girl with a
2-year history of selective mutism and associated
shyness.30 The dosage was titrated to 37.5
mg/day, and within 6 weeks, the child began to
speak freely outside the home.  Further improve-
ment was noted as the dosage was increased to
60 mg/day.
In the second report, three children demon-
strated similar responses; one had previously
received fluoxetine therapy without success.31
Phenelzine treatment, administered for 24–60
weeks, was not associated with recurrence of
mutism; one patient was followed for 8 years
after the drug was discontinued and experienced
no recurrence.  Phenelzine was generally well
tolerated, although weight gain, mild
constipation, insomnia, low blood pressure, and
bladder retention were documented.  The authors
postulated that selective mutism, like social
phobia, might respond to the serotonergic and
dopaminergic actions of this agent.
Because of significant food and drug inter-
actions and dietary restrictions with phenelzine,
the drug is administered only as a second-line
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agent for patients who fail treatment with an
SSRI.  However, phenelzine may be of particular
benefit for a child with concomitant conditions
such as enuresis, obsessive-compulsive symptoms,
anxiety, or irritability.
Selective Serotonin Reuptake Inhibitors
No published trials were located comparing the
SSRIs with other treatments for management of
selective mutism.  However, SSRIs may be
considered first-line pharmacologic treatment for
selective mutism because of the predominance of
reports in the literature and due to the relative
safety and established efficacy of these agents in
other childhood psychiatric disorders.8, 44 In one
report, SSRIs were effective in 11 (65%) of 17
children with selective mutism according to
parent assessment.45
Although the specific mechanism by which
SSRIs may improve selective mutism is unknown,
there may be an underlying imbalance in central
nervous system serotonin that is corrected by
SSRI therapy. The SSRIs further serotonergic
activity by reducing presynaptic serotonin
reuptake, with only weak effects on other
neurotransmitters.  Some authors have suggested
that disinhibition, a dopaminergic effect, may
account for the rapid response (within 1 wk)
noted in some patients with selective mutism
who received SSRI therapy.35, 41 In contrast,
others reported efficacy only after 7–12 weeks of
therapy, perhaps due to serotonin-mediated
reductions in anxiety.33, 34, 37, 38 Of the
commercially available SSRIs, fluoxetine,
fluvoxamine, sertraline, and paroxetine have
been used as treatment for children with selective
mutism (Table 1).32–43
Fluoxetine. Fluoxetine is the most studied SSRI
administered in children with selective mutism;
several clinical studies and case reports are cited
in the literature.32–39, 43 Interest in fluoxetine for
selective mutism probably developed from its
efficacy in treating social phobia in 10 (71%) of
14 adults, as reported in 1992.46
In another 1992 report, a 12-year-old girl with
a several-year history of social phobia and
selective mutism was described.32 Her condition
did not respond to two outpatient psychotherapy
programs.  After only slight improvement with
desipramine, her treatment was changed to
fluoxetine 20 mg every other day for 7 days and
then 20 mg/day.  Within 4 weeks, dramatic
improvement was noted in her verbal communi-
cation with both peers and adults, and her social
avoidance essentially resolved.  This positive
response was maintained at 7 months of
continued fluoxetine therapy.
These findings led the same authors to conduct
a randomized, double-blind, placebo-controlled
evaluation of the efficacy of fluoxetine in
children with selective mutism.33 The study was
conducted in two phases and initially included
16 pediatric patients with selective mutism for a
mean ± SD of 5.8 ± 2.7 years.  All 16 had social
phobia or avoidant disorder of childhood; six
also had other psychiatric disorders.  The total
number of psychiatric diagnoses was evenly
distributed between treatment groups.
The first single-blind phase, in which all
patients received placebo, lasted 2 weeks and was
designed to eliminate placebo-responders.  One
child was subsequently excluded, and the rest
were randomized to receive fluoxetine (six
patients) or placebo (nine) in the second, 12-
week, double-blind phase.  The investigators
followed a dosage titration scale for the children
receiving fluoxetine, starting with 0.2 mg/kg
once/day for the first week, increasing to 0.4
mg/kg/day for week 2 and to 0.6 mg/kg/day for
the remaining 10 weeks.
The patient, psychiatrist, parents, and teachers
assessed the changes in mutism, anxiety, shyness,
and global clinical impression ratings and
completed several assessment scales before the
single-blind phase, at baseline just before the
double-blind treatment phase, and every 2 weeks
or 4 weeks (teachers) for 12 weeks.  A mean
mutism severity score was also calculated, based
on the evaluation of speaking in common social
situations.
Mean maximum fluoxetine dose was 21.4
mg/day (range 0.60–0.62 mg/kg/day).  Overall,
the fluoxetine-treated patients demonstrated
improved group means in 28 of 29 rating scales,
yet few changes were statistically significant.
Effects were most apparent during weeks 8–12 of
fluoxetine therapy.  The parents documented
significant improvements from baseline in eight
of nine ratings over time.  The differences between
fluoxetine and placebo in mutism and global
change scores were statistically significant and
favored fluoxetine (p<0.0003 and p<0.04,
respectively).
Although improvements from baseline were
noted in six of nine clinician assessment tools, no
statistically significant differences were noted
between treatment groups.  Significant improve-
ments over time in all 10 ratings were reported
by teachers for both treatment groups.  Only the
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change in rating for anxiety was significantly
more improved with fluoxetine than placebo;
however, fluoxetine recipients had higher scores
throughout the study, from baseline to the end of
treatment.
No significant improvements were noted in the
few patient self-ratings collected.  The proportion
of patients deemed responders was higher in the
fluoxetine group according to evaluations
conducted by parents, but not by clinicians or
teachers.  Of note, patient and teacher assessment
of improvements in individual patients were
correlated (p≤0.03).  Most patients remained
symptomatic at the end of the study; the number
of patients whose selective mutism resolved was
not provided.  Adverse effects with fluoxetine
were minimal and did not differ significantly
from those with placebo.
Although this study provided important
information regarding the potential efficacy of
fluoxetine therapy in children with selective
mutism, interpretation of the results is limited by
219
Table 1.  Summary of Studies of Selective Serotonin Reuptake Inhibitors for Treatment of Selective Mutism
Drug, Sex, Treatment
Study Design Age (yrs) Treatment Duration Outcome
Fluoxetine
Case report F, 12 Fluoxetine 20 mg q.o.d. x 7 days, 7 mo Improved within 4 wks
(n=1)32 then 20 mg q.d.
Case report F, 6 Dosage not specified NR Improved
(n=1)39
R, DB, PC; 6 M, 9 F; Placebo x 2 wks, then fluoxetine 12 wks Fluoxetine-treated patients improved
fluoxetine fluoxetine titrated to 0.6 mg/kg q.d. or according to parent ratings, but not
group (n=6), group: placebo according to most clinician and
placebo 9.1 ± 2.3 teacher ratings





Case report F, 4 Fluoxetine 4 mg q.d. initially, 1 yr Improved in 5 days; positive response
(n=1)35 then increased to 8 mg q.d. maintained at 1 yr
Case report F, 12 Placebo x 13 days, then 6 wks Improved within 2 wks; positive
(n=1)36 fluoxetine 20 mg q.d. response maintained 1 yr after drug
discontinuation
Open-label 5 M, 16 F; Fluoxetine titrated to 60 mg q.d. 9 wks Improvement seen on all assessment
(n=21)34 5–14 (maximum); mean final daily scales
dose 1.1 mg/kg
Case report M, 8 Fluoxetine 20 mg q.d. x 1 mo, 7 wks Improved at 7 wks
(n=1)37 then 30 mg q.d. x 3 wks
Case report F, 5 Fluoxetine 20 mg q.d., then 9 mo Improved within 3 mo; improved
(n=1)43 30 mg q.d. + haloperidol response after 1 mo of combination
0.5 mg b.i.d. therapy
Case report F, Fluoxetine 0.3 mg/kg q.d., 18 mo All patients improved within 8–10 wks
(n=4)38 5–17 increased to 0.6 mg/kg q.d. (n=1)
(n=1); dosage NR (n=3)
Fluvoxamine
Case report F, 6.5 Fluvoxamine 50 mg q.d. x 2 wks, 6 mo Improved after 2 wks 2 days
(n=1)40 then 100 mg q.d.
Sertraline
3-phase, DB, 1 M, 4 F; Placebo x 2–6 wks, then 8–12 wks All patients improved by week 16
single-case 5–11 sertraline 50 mg q.d. x 2 wks, according to parent ratings
design then 100 mg q.d. x 6–10 wks
(n=5)41
Paroxetine
Case report F, 8 Paroxetine 5 mg q.d. 3 yrs Improved within 2–3 wks
(n=1)42
R = randomized; DB = double-blind; PC = placebo controlled; NR = not reported.
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the small sample size and more severe symptoms
in the fluoxetine group at baseline.  Because
much of the fluoxetine benefit was noted after 8
weeks, a longer treatment duration at the higher
doses might affect outcomes.  Continued mutism
with the treating clinician while the child’s
symptoms are improving at home or in school is
consistent with previous reports.  However, the
authors surmised that early treatment effects
noted in the home and neighborhood by parents
might be extended to improvements in school
with a longer treatment duration.
The time of treatment in relation to the school
year might also have influenced the results.  This
study was conducted in the second half of the
school year.  Starting therapy in the summer
months might improve the chances of a positive
outcome.  At the beginning of the school year,
peers and teachers would have fewer precon-
ceived notions regarding lack of speaking to
overcome.
Another group of authors evaluated the
efficacy of fluoxetine for treatment of selective
mutism in 21 children (aged 5–14 yrs) with
concurrent anxiety disorders in a 9-week open-
label trial.34 Weekly supportive psychotherapy
was provided to all patients during the study.  In
an attempt to decrease adverse effects, fluoxetine
was slowly titrated from 1.25 mg/day the first
week to 20 mg/day after approximately 4 weeks
in the first 10 children enrolled.  If no clinical
improvement occurred by week 7, the fluoxetine
dosage was increased to 40 mg/day and again to
60 mg/day after 2 weeks if needed.  The protocol
was revised for faster fluoxetine titration in the
next 11 patients.  Assessments were conducted
by a psychiatrist and included patients’ self-
ratings and parents’ evaluation of symptoms and
behavior.
Mean fluoxetine dose at the end of the trial was
28.1 mg/day (1.1 mg/kg/day, range 10–60
mg/day); optimal response was noted with 20
mg/day.  At the end of 9 weeks, 16 (76%) of 21
children showed improvement on the Clinical
Global Improvement Scale.  The response rate
was similar for boys and girls and was inversely
correlated with age.
Statistically significant improvements in scores
were seen with all clinical outcome instruments
at week 9.  On the Children’s Global Assessment
Scale, with scores of 0–100 indicating lowest to
highest function, the patients improved from a
mean ± SD score of 47.1 ± 9.0 at baseline to 67.5
± 13.0 (p<0.001).  Similarly, on the Liebowitz
Social Anxiety Scale and the Social Avoidance
Scale scores, both ranging from 0–72, with lower
scores predicting better function, improved from
48.2 ± 13.7 to 27.5 ± 18.9 (p<0.001) and from
45.4 ± 13.1 to 27.5 ± 22.1 (p<0.001),
respectively.  Treatment benefits as assessed by
patients (p<0.001) and parents (p<0.005) were
also documented on the Social Behavior Scales.
Nine (43%) of the 21 patients had adverse
effects, including excitement or disinhibition
(four patients), insomnia (two), jitteriness (two),
and headache (two).  These were generally short-
lived, lasting less than 1 week.  However, therapy
was discontinued in two of the children with
behavioral disinhibition.  No changes were
observed in heart rate, blood pressure, or weight.
The authors concluded that fluoxetine is safe
and effective for treatment of selective mutism in
conjunction with psychotherapy in children aged
5 years or older.  However, the lack of a placebo
group and the small study population may limit
interpretation of results.  Fluoxetine was
gradually titrated to avoid potential dose-related
adverse effects, such as behavioral disinhibition.
However, the slow initial titration (4–9 wks),
muddled by the titration protocol change, may
have affected outcomes.  Complete remission of
selective mutism may require a longer treatment
duration at the minimal effective dose than was
provided by the 9-week study duration.
Success with fluoxetine therapy has also been
documented in case reports involving patients
with selective mutism.35–39 One group described
fluoxetine administration in a 4-year-old girl with
a 15-month history of selective mutism.35 After
presenting with a 9-month history of the
disorder, the child benefited somewhat from a
12-week outpatient preschool diagnostic and
intervention day program.  However, she still was
not speaking at the end of the program or after
another 3 months of weekly behavioral
treatment.  Fluoxetine 4 mg/day was then started,
and within 5 days, the girl began to speak in
familiar settings.  The dose was increased to 8
mg/day by day 12, and she was talking comfortably
in all settings by day 20.
After 18 months, the patient’s scores for
internalizing symptoms, withdrawal and somatic
complaints, and difficulties with mood and
adaptability decreased from clinically significant
to having borderline significance.  In contrast,
scores indicating social problems, hyperactivity,
and distractibility worsened as the child
responded to fluoxetine therapy. No adverse
effects were noted.  Fluoxetine and monthly
family therapy were still effective after 1 year.
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The treatment duration required to maintain
response for selective mutism remains unclear.
One author described a 12-year-old Turkish girl
with an 8-year history of selective mutism who
had a sustained response after 6 weeks of SSRI
therapy.36 The patient would speak only to her
mother and a few siblings and friends; she used
gestures and writing to communicate with
others.  Her communication levels did not
change after a 13-day placebo trial.  Fluoxetine
20 mg/day was then begun.  Within 2 weeks, the
patient was less withdrawn, and started talking to
her father and brothers as well as her physician.
Fluoxetine therapy was continued for 4 more
weeks with no adverse effects.  Treatment was
then stopped, and the patient continued speaking
during the next 12 months.
In another report, an 8-year-old boy was
hospitalized after 4 years of selective mutism
accompanied by 1 year of aggressive behavior.37
Two weeks after admission, fluoxetine 20 mg/day
was started.  After 1 month, the dose was
increased to 30 mg/day (1 mg/kg/day), and
behavioral interventions were begun.  After 3
weeks, the patient started speaking.
The benefits of fluoxetine were also demon-
strated in four girls aged 5–17 years who had not
responded to 1–2 years of psychotherapy.38 One
girl showed marked improvement within 6 weeks
of the start of fluoxetine therapy; full effects were
noted within 3 months.  In another case report, a
6-year-old girl with a 2-year history of selective
mutism after poor response to psychotherapy
improved with fluoxetine therapy.39 However,
dosage and time to effect were not provided.
Clinical trials of drug combinations in patients
with selective mutism have not been conducted.
However, addition of haloperidol to fluoxetine
therapy benefited one patient with Tourette’s
syndrome and selective mutism.43 This child,
who developed selective mutism at 5 years of age,
initially responded to treatment with fluoxetine
20 mg/day and behavioral therapy, and was
speaking to family members after 3 months.
After a trial with clonidine for increasingly
aggressive behavior, haloperidol 0.5 mg at
bedtime was added to the patient’s regimen of
fluoxetine 30 mg/day.  Haloperidol was increased
to twice/day without notable adverse effects.
Within 1 month of this combination therapy, the
child was communicating in various settings with
diminished vocal and motor tics.
Fluvoxamine. Unlike fluoxetine, no clinical
studies have formally evaluated fluvoxamine
therapy for selective mutism.  However, this SSRI
has been effective in the management of a variety
of pediatric anxiety disorders.47 In one case
report, fluvoxamine was administered to a 6.5-
year-old girl with selective mutism and obsessive-
compulsive traits.40 The child’s social withdrawal
tendency began when she was 4 years old; she
was diagnosed with selective mutism the next
year at school entry.  Several months of
psychotherapy were ineffective.  Fluvoxamine 50
mg/day (1.8 mg/kg/day) was started and was
increased to 100 mg/day when no response was
noted after 2 weeks.  Within 2 days, the patient’s
verbal communication improved dramatically
and her obsessive symptoms completely resolved.
Within 4 weeks, however, the child began to
experience a hypomanic syndrome characterized
by hyperactivity, decreased sleep, distractibility,
and self-endangering behavior (e.g., jumping
from furniture).  These symptoms improved with
reduction of the fluvoxamine dosage to an
alternating schedule of 50 mg/day and 100
mg/day, and resolved after the start of lithium
carbonate therapy.  Six months later, the selective
mutism remained in relative remission, but
manic symptoms were noted and fluvoxamine
was discontinued.  Nine months after the SSRI
was discontinued, the patient was still speaking,
although oppositional behaviors remained
problematic, and some obsessive symptoms
recurred.
Sertraline. In 1999, a group of authors reported
the efficacy of sertraline as treatment for selective
mutism.41 Five children, aged 5–11 years, were
included in this three-phase, 16-week, double-
blind study.  The first phase consisted of 2 weeks
with no drug treatment.  The second phase
involved administration of placebo for 2–6
weeks.  In the third phase, each child was given
sertraline 50 mg/day for 2 weeks followed by 100
mg/day for 6–10 weeks, depending on the length
of the placebo phase.  No group changes in
mutism, anxiousness, and shyness were
measured.  Weekly parent Goal Attainment Scale
ratings showed improvements in four of the five
patients within 1 week of the start of sertraline
therapy; response was noted in the remaining
patient in week 5 of active treatment.
At week 16, parent ratings on the Goal
Attainment Scale indicated improved levels of
speech in all five patients.  Similarly, parents
observed some improvement in spontaneous
speaking during sertraline therapy in four
children.  Teachers, however, observed speaking
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in only two of these four at school.  All five
patients continued receiving sertraline 100
mg/day and maintained improvements in
mutism, anxiety, and shyness ratings 4 weeks
after study end.  By 20 weeks after study end,
three patients no longer met the diagnostic
criteria for selective mutism:  two who were
receiving sertraline 50 mg/day and one whose
drug therapy was discontinued.  The remaining
two patients continued receiving sertraline 100
mg/day.  Their mutism improved in some
settings, although they still did not speak in the
classroom.
Acceptability of sertraline treatment and
overall patient compliance were high.  Few
adverse effects occurred, although insomnia was
reported by one patient 2 weeks after the dose
increase in phase 3.
In addition to its small sample size and lack of
standardized scales to assess selective mutism,
this study is limited by its nonconcurrent
multiple baseline design and, subsequently, the
inability to apply statistical methods to the data.
Although each patient improved relative to
baseline, the onset of increased speech did not
correspond to the start of sertraline therapy.
Therefore, the internal validity of the multiple
baseline design was not established.
Paroxetine. The efficacy of paroxetine was
reported in an 8-year-old girl with significant
social anxiety disorder and selective mutism that
was diagnosed when she was 5 years old.42 The
child refused to speak to anyone except her
parents and siblings, and only at home.
Paroxetine 5 mg at bedtime was started without
concomitant psychotherapy.  Within 2–3 weeks,
her family and teachers noted a dramatic
response in both selective mutism and anxiety;
the patient was communicating verbally at school
and in other social settings.  She received
paroxetine for 3 years without relapse of selective
mutism.
Limitations
The few clinical studies and case reports
available regarding SSRI administration to treat
selective mutism have several notable limitations.
Most trials had small sample sizes and included
children from a referred sample.  These patients
might have more severe symptoms than a general
patient population with selective mutism.
Fluoxetine was the SSRI administered in most
reports; doses of other SSRIs were relatively low,
making assessment of comparative efficacy
difficult.  In addition, because only a few double-
blind studies exist, a placebo effect cannot be
fully excluded.  Further, the positive outcomes
noted in case reports may be misleading, since
reports of similar patients in whom treatment
was unsuccessful are less likely to be published.
The trials were short, consisting of only 6–10
weeks of SSRI therapy.33, 34, 41 Follow-up was
reported in only one study.41 No validated
assessment tools have been established for
evaluating treatment outcomes in children with
selective mutism.  Instead, assessments of
efficacy vary; for example, modified scales for
social anxiety, behavior, and depression have
been used.41
The setting of observations may also affect
results, since children may remain mute at the
clinic while improving at home and at school.  In
addition, variable timing of SSRI therapy may
affect response rates; efficacy might be enhanced
if SSRIs were started before or early in the school
year.33
Recommendations for Optimizing Therapy
The long-term consequences of selective
mutism are unclear, but the condition may be
associated with impaired school achievement,
self-esteem, and socialization.23 Some authors
have argued that early diagnosis and intervention
result in a better prognosis,35 but this is largely
unproven.  Because of the inherent risks and
sparse data regarding the long-term benefits of
drug therapy, management of selective mutism
should begin with psychotherapy.3, 8, 27
Behavioral interventions or cognitive-behavioral
therapy alone or in conjunction with family and
speech therapies may be indicated, depending on
the individual patient.  Treatment should focus
on encouraging the child to interact and
communicate by reducing symptoms of anxiety
and avoiding reinforcement of the mutism.2, 3
If the child does not respond to psychotherapy,
the decision to add drug therapy depends on
factors such as the severity of selective mutism
symptoms, history of previous treatment
attempts, and identification of comorbid illnesses
that might benefit from therapy (e.g., anxiety,
obsessive-compulsive disorder).  The support by
parents and teachers of a multimodal approach
incorporating both psychotherapy and
pharmacologic management is needed to increase
the likelihood of positive outcomes.
The SSRIs are well tolerated; the frequency of
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cardiac events and anticholinergic adverse effects
is lower than that with tricyclic antidepressants.
Adverse effects noted with SSRIs in clinical trials
and case reports of children with selective
mutism were generally described as mild and
transient.  These effects included gastrointestinal
and sleep disturbances, jitteriness, drowsiness,
headache, and decreased appetite.  However,
increases in oppositional and disinhibitory
behavior and hypomania also were reported.34, 40
The patient’s family should also be made aware of
the risk of serotonin syndrome and withdrawal
reactions.
In 2004, the FDA required that SSRI manu-
facturers add to package labeling a black-box
warning of the potential for suicidal ideation and
behaviors after administration of these agents to
pediatric patients.48 More recently, a meta-
analysis did not document a statistically
significant increased risk of suicidality with
obsessive-compulsive disorder or other anxiety
disorders.49 However, close monitoring of
patients is recommended, especially during the
first few months of SSRI therapy.
Randomized, placebo-controlled trials involving
larger numbers of patients followed for longer
durations are required to delineate the optimal
course of SSRI therapy for selective mutism.
Since most experience with SSRI treatment in
these patients to date involves fluoxetine, this
agent is preferred.  One study reported optimal
efficacy with a dosage of 20 mg/day.34 Response
has occurred as early as within 1 week of the
start of SSRI treatment but may not be apparent
until up to 12 weeks.  Thus, it seems prudent to
administer adequate SSRI doses for at least 3
months before deeming therapy a failure.  The
optimal treatment duration after resolution of
selective mutism also remains unclear.  In one
case report, therapy was continued for 3 years.42
In contrast, sustained remissions of up to 1 year
have been documented after discontinuation of
SSRI therapy.36, 40, 41
Conclusion
Selective mutism is a rare psychiatric disorder
in which a child consistently fails to speak in
specific situations in which speaking is expected,
but speaks appropriately in other settings.
Although children with the condition are often
treated with psychotropic agents, only limited
literature describes the efficacy of drug therapy
for selective mutism.  After the failure of
psychotherapy alone, a trial with fluoxetine may
be suggested, with close monitoring for serious
adverse effects associated with SSRI adminis-
tration in children and adolescents.  Much
remains to be learned about the course of
selective mutism, including the choice and
required duration of therapy.
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